Fig. 5
From: Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion
Infliximab inhibits the cytotoxic activity of M0 macrophages. a BrdU proliferation assay of PANC-1 and MIA PaCa-2 cells in RPMI-1640 (negative-control) or M0-CM with 25 μg/ml Infliximab where indicated. On the figure shown is the mean ± SEM (n = 4); One-way ANOVA was used to assess statistical significance. b Annexin V-FITC positive cells in control, M0-CM with or without 25 μg/ml Infliximab where indicated, or Gemcitabine (as positive control) treated PANC-1 and MIA PaCa-2 cells at t = 48 h. Plotted is the Geometric Mean Fluorescent Intensity (gMFI) on the FITC channel (Annexin V density). On the figure shown is the mean ± SEM (n = 3); One-way ANOVA was used to assess the significance. c Annexin V-FITC positive cells in control, M0 M-CSF, or M0 GM-CSF with or without 25 μg/ml Infliximab where indicated, or Gemcitabine (as positive-control) treated PANC-1 and MIA PaCa-2 cells at t = 48 h. Plotted is the Geometric Mean Fluorescent Intensity (gMFI) on the FITC channel (Annexin V density). On the figure shown is the mean ± SEM (n = 3); One-way ANOVA was used to assess the significance